Pharma BD Deal Intelligence
Adakveo got approved but never became the blockbuster Novartis paid for, then lost Europe entirely after a confirmatory trial flop
Full analysis, sources & comparables →Novartis paid up to $665M for SelG1, a first-in-class anti-P-selectin antibody, after a Phase 2 SUSTAIN readout cut vaso-occlusive crises by 47% versus placebo…
"Novartis has acquired US-based hematologic and inflammatory disorder therapeutics developer Selexys Pharmaceuticals in a deal valued at approximately…
EMA's CHMP recommended revoking Adakveo's marketing authorization after the STAND confirmatory Phase 3 showed no benefit (2.5 vs 2.3 painful crises) and worse…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novartis exercised its right to acquire Selexys Pharmaceuticals (held since 2012 option) for ~$665M total consideration following positive Phase 2 SUSTAIN data. Lead asset SelG1, an anti-P-selectin antibody for vaso-occlusive crises in sickle cell disease. Approved as Adakveo (crizanlizumab) in November 2019 (subsequently withdrawn EU 2023 after Phase 3 failure).
Adakveo got approved but never became the blockbuster Novartis paid for, then lost Europe entirely after a confirmatory trial flop
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Selexys Pharmaceuticals (this deal) | 2016 | $665M | 37 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2016 deals · Novartis AG deals · Hematology deals